Exchange: NYSE·Updated 07:37 PM EDT
News
all
press releases
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie leverages a strong specialty drug portfolio to offset the loss of exclusivity for its former top-selling products...
Nasdaq News: Markets
More News
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.
Zacks
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?
Key PointsAbbVie has been willing to supplement its new drug pipeline through acquisitions...
Nasdaq News: Markets
AbbVie's (ABBV) Botox Just Got A Step Closer To A Fifth Use
AbbVie's (ABBV) Botox Just Got A Step Closer To A Fifth Use...
Yahoo! Finance: News
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
Key PointsAbbVie's growth rate was more than 10% this past quarter and has been rising in recent years...
Nasdaq News: Markets
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie relies on a high-margin biopharmaceutical portfolio and significant free cash flow to drive shareholder value...
Nasdaq News: Markets
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
Zacks
AbbVie Takes Over #60 Spot From International Flavors & Fragrances
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, AbbVie Inc (Symbol: ABBV) has taken over the #60 spot from International Flavors & Fragrances Inc. (Symbol: IFF), according to ETF Channel. Below is a chart of A...
Nasdaq News: Markets
S&P 500 Analyst Moves: ABBV
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #60 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each bro...
Nasdaq News: Markets
ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?
ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.
Zacks

Advertisement|Remove ads.